



UroGen Pharma to Present at Upcoming Investor Conferences

March 1, 2023

PRINCETON, N.J.--(BUSINESS WIRE)--Mar. 1, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in March:

Cowen 43rd Annual Health Care Conference —March 7-9, 2023

- Panel Presentation Date: Tuesday, March 7th from 12:50-1:50pm ET
- Webcast Link: <https://wsw.com/webcast/cowen132/panel12/2317014>

Oppenheimer 33rd Annual Healthcare Conference —March 13-15, 2023

- Presentation Date: Tuesday, March 14th from 10:40-11:10am ET
- Webcast Link: <https://wsw.com/webcast/oppenheimer27/urgn/2810892>

Webcasts for both the Cowen and Oppenheimer presentations will be available via the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the Company's website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product JELMYTO (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230301005965/en/): <https://www.businesswire.com/news/home/20230301005965/en/>

INVESTOR CONTACT:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano
UroGen Corporate Communications
cindy.romano@urogen.com
908-963-7827

Source: UroGen Pharma Ltd.